Federal Contractor Profile
Albert B. Sabin Vaccine Institute, INC. (the)
Federal contracting record: $306M obligated across 2 awards from 1 agencies, FY 2019–2025.
$306M
Total Obligated
2
Award Records
1
Agencies Served
1
NAICS Codes
Company Profile
UEI (Unique Entity Identifier)
H5E8NU6N2HZ5
CAGE Code
5MPW2
Parent Organization
Albert B. Sabin Vaccine Institute, INC. (the)
Address
2175 K STREET NW SUITE 400, WASHINGTON, DC, 200371848
First Federal Award
Sep 26, 2019
Most Recent Award
Jul 29, 2025
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- $306M
Department of Health and Human Services
2 awards · 100.0% of total
Top NAICS Activity
- $306M
541714
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
2 awards
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Jul 29, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $39M |
| Jul 8, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $1.6M |
| May 1, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $13M |
| Dec 16, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $17M |
| Sep 25, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $17M |
| Jul 23, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $2.5M |
| May 21, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $777K |
| Aug 23, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $28M |
| Aug 2, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $36M |
| Feb 14, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $799K |
| Dec 29, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $35M |
| Dec 19, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $861K |
| Oct 21, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $16M |
| Aug 17, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $22M |
| May 27, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $463K |
| Jan 18, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $1.2M |
| Sep 1, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $35M |
| May 5, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $20M |
| Sep 26, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $21M |
Related Contractors
Other companies active in NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY).
Track Albert B. Sabin Vaccine Institute, INC. (the) Recompetes Before They Post
Mindy monitors Albert B. Sabin Vaccine Institute, INC. (the)'s active contracts and alerts you 12 months before they expire — so you can position to compete on recompete.
Get Free Recompete Alerts